# Adult Medication Monograph

## AMOXICILLIN (AMOXYCILLIN) with CLAVULANIC ACID

This document should be read in conjunction with this DISCLAIMER

**Antimicrobial Restriction – Unrestricted**

| Presentation | Tablet: 875mg/125mg  
<table>
<thead>
<tr>
<th></th>
<th>Oral liquid: 400mg/57mg in 5mL</th>
</tr>
</thead>
</table>
| Dose         | **Cystitis:**  
|             | Oral:  
|             | 875/125mg 12 hourly for 5 to 7 days  
|             | **Pelvic Inflammatory Disease:**  
|             | Oral:  
|             | 875/125mg 12 hourly for 2 to 4 weeks (once on oral therapy)  
|             | **Endometritis** – For less unwell patients where oral antibiotics are deemed sufficient or for empiric step down therapy  
|             | Oral:  
|             | 875/125mg 12 hourly for 2 weeks  
| Administration | Oral:  
|             | To be taken immediately before food, to maximise absorption  
| Pregnancy    | **1st Trimester:** Safe to use  
|             | **2nd Trimester:** Safe to use  
|             | **3rd Trimester:** Safe to use  
|             | **NOTE:** Should be avoided in women with preterm rupture of membranes due to an increased risk of neonatal necrotising enterocolitis (NEC).  
| Breastfeeding | Safe to use  
| Monitoring   | Monitor complete blood count and renal and hepatic function during prolonged high-dose treatment (>10 days)  
| Clinical guidelines and | KEMH Clinical Guideline: O&G: Infections: [Urinary tract infection in pregnant women](#)
KEMH Clinical Guideline: O&G: Gynaecology (Non-Oncological) (Acute Pelvic Inflammatory Disease on page 2)

WNHS Policy: Antimicrobial Stewardship


Keywords: amoxycillin, amoxicillin, clavulanic acid, clavulanate, augmentin, aug DF, UTI, urinary tract infection, cystitis, PID, pelvic inflammatory disease, STI, endometritis, salpingitis, parametritis, oophritis, pelvic peritonitis

Publishing: ☑ Intranet ☑ Internet

Document owner: Chief Pharmacist

Author / Reviewer: Pharmacy Department

Date first issued: November 2014

Last reviewed: March 2017, Jan 2019

Endorsed by: Medicine and Therapeutic Committee

Next review date: Jan 2022

Date: Jan 2019

Standards Applicable: NSQHS Standards: 1 Governance, 3 Infection Control, 4 Medication Safety

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2019